RESUMEN
OBJECTIVES: To investigate catechol-O-methyltransferase (COMT) Val158Met gene polymorphism in MDMA use disorder (MUD) by comparing genotype distributions between MUD patients and healthy controls considering clinical parameters. METHODS: Eighty-two MUD patients' were consecutively admitted to the outpatient psychiatry clinic in May 2019-January 2020, and 95 healthy volunteers were included in the case-control study. We used the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) to determine COMT Val158Met polymorphism. RESULTS: The COMT Val158Met genotype distribution and allele frequencies of the MUD patient group were significantly different from the healthy control group. The Met/Met genotype (OR: 2.692; 95% Cl: 1.272-5.698; p=0.008) and Met allele frequencies (OR: 1.716; 95% Cl: 1.118-2.633; p=0.013) were significantly higher in the control group than in MUD patients. When the COMT Val158Met genotype and allele frequency distributions were compared between 2 groups according to the psychotic symptoms in the MUD patient group, the COMT Val158Met genotype distributions were significantly different between the groups of patients. The percentage of patients with the Val/Val genotype was significantly lower in MUD patients with a psychotic symptom than the MUD patients without a psychotic symptom (OR: 2.625; 95% Cl: 1.069-6.446; p=0.033). CONCLUSION: The COMT Val158Met gene polymorphism was found to be related to the MUD-diagnosed Turkish patients and MDMA-induced psychotic symptoms.
Asunto(s)
Catecol O-Metiltransferasa , N-Metil-3,4-metilenodioxianfetamina , Psicosis Inducidas por Sustancias/genética , Estudios de Casos y Controles , Catecol O-Metiltransferasa/genética , Genotipo , Humanos , N-Metil-3,4-metilenodioxianfetamina/efectos adversos , Polimorfismo de Nucleótido Simple , TurquíaRESUMEN
Objective: This review discusses the relationship between cannabis use and psychotic, bipolar, depressive, and anxiety disorders, as well as suicide. It summarizes epidemiological evidence from cross-sectional and long-term prospective studies and considers possible etiological mechanisms. Methods: Systematic reviews and methodologically robust studies in the field (from inception to February 2019) were identified using a comprehensive search of Medline, PsychINFO, and Embase and summarized using a narrative synthesis. Results: Consistent evidence, both from observational and experimental studies, has confirmed the important role of cannabis use in the initiation and persistence of psychotic disorders. The size of the effect is related to the extent of cannabis use, with greater risk for early cannabis use and use of high-potency varieties and synthetic cannabinoids. Accumulating evidence suggests that frequent cannabis use also increases the risk for mania as well as for suicide. However, the effect on depression is less clear and findings on anxiety are contradictory with only a few methodologically robust studies. Furthermore, the relationship with common mental disorders may involve reverse causality, as depression and anxiety are reported to lead to greater cannabis consumption in some studies. Pathogenetic mechanisms focus on the effect of tetrahydrocannabinol (THC, the main psychoactive ingredient of cannabis) interacting with genetic predisposition and perhaps other environmental risk factors. Cannabidiol (CBD), the other important ingredient of traditional cannabis, ameliorates the psychotogenic effects of THC but is absent from the high-potency varieties that are increasingly available. Conclusions: The evidence that heavy use of high-THC/low-CBD types of cannabis increases the risk of psychosis is sufficiently strong to merit public health education. Evidence of similar but smaller effects in mania and suicide is growing, but is not convincing for depression and anxiety. There is much current interest in the possibility that CBD may be therapeutically useful.
Asunto(s)
Trastornos de Ansiedad , Trastorno Bipolar , Moduladores de Receptores de Cannabinoides/efectos adversos , Trastorno Depresivo , Predisposición Genética a la Enfermedad , Uso de la Marihuana/efectos adversos , Psicosis Inducidas por Sustancias , Suicidio , Trastornos de Ansiedad/inducido químicamente , Trastornos de Ansiedad/genética , Trastorno Bipolar/inducido químicamente , Trastorno Bipolar/genética , Trastorno Depresivo/inducido químicamente , Trastorno Depresivo/genética , Predisposición Genética a la Enfermedad/etiología , Predisposición Genética a la Enfermedad/genética , Humanos , Psicosis Inducidas por Sustancias/etiología , Psicosis Inducidas por Sustancias/genéticaRESUMEN
BACKGROUND: Various antiepileptic drugs can potentially cause psychiatric side effects in patients with epilepsy, but the precise mechanism of these actions remains unknown. In recent years, the common polymorphism C677T in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene has attracted attention for its role in the onset of psychiatric diseases. MTHFR and several vitamins (as cofactors) are crucial for remethylation of homocysteine via folate and homocysteine metabolism. We report a case of a Japanese patient who presented with reversible schizophrenia-like symptoms during antiepileptic drug therapy. CASE PRESENTATION: Our patient had frontal lobe epilepsy and had been treated with several antiepileptic drugs since the age of 13 years. He developed auditory hallucinations and multiple personalities at 17 years of age, several months after the initiation of phenytoin and phenobarbital, despite these antiepileptic drugs being used within the therapeutic ranges. Genetic analysis revealed that he was homozygous for the C677T polymorphism of MTHFR. Hyperhomocysteinemia, hypomethionemia, and multiple vitamin deficiencies, including folate, riboflavin, and pyridoxal, were identified at the age of 23 years. Vitamin supplementation and alteration of the antiepileptic drugs improved his psychotic symptoms. Multiple vitamin deficiencies with homozygous MTHFR C677T should be considered in patients presenting with schizophrenia-like symptoms during antiepileptic drug therapy. CONCLUSIONS: To the best of our knowledge, this is the first report of antiepileptic drug-induced psychosis associated with homozygous C677T and multiple vitamin deficiencies. Our findings will contribute to the elucidation of the pathogenesis of the psychiatric side effects of antiepileptic drugs and lead to improved medical management for patients with epilepsy.
Asunto(s)
Anticonvulsivantes/efectos adversos , Epilepsia/tratamiento farmacológico , Fenobarbital/efectos adversos , Fenitoína/efectos adversos , Psicosis Inducidas por Sustancias/etiología , Adolescente , Avitaminosis/complicaciones , Humanos , Masculino , Metilenotetrahidrofolato Reductasa (NADPH2)/deficiencia , Polimorfismo Genético , Psicosis Inducidas por Sustancias/diagnóstico , Psicosis Inducidas por Sustancias/genética , Adulto JovenRESUMEN
A BDNF rs6265 [A/A] by gender by cannabis use interaction has been associated with age of onset of psychosis (AoP). We examined the gender and cannabis use-adjusted association between BDNF rs6265 [G>A] and AKT1 rs2494732 [T>C] and AoP. Data from 167 Caucasians on AoP and age at first regular cannabis use were collected. Kaplan-Meier and Cox regression analyses were conducted. A trend level gene-gender interaction effect was observed for the BDNF rs6265 A/A genotype, controlling for age at first regular cannabis use. Larger collaborative research projects are required to further investigate this effect.
Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/genética , Epistasis Genética/genética , Variación Genética/genética , Fumar Marihuana/genética , Psicosis Inducidas por Sustancias/genética , Caracteres Sexuales , Adolescente , Adulto , Edad de Inicio , Femenino , Humanos , Masculino , Fumar Marihuana/efectos adversos , Fumar Marihuana/psicología , Polimorfismo de Nucleótido Simple/genética , Psicosis Inducidas por Sustancias/diagnóstico , Psicosis Inducidas por Sustancias/psicología , Adulto JovenRESUMEN
Importance: Previous research indicates that cannabis use is associated with psychotic-like experiences (PLEs). However, it is unclear whether this association results from predispositional (ie, shared genetic) factors or individual-specific factors (eg, causal processes, such as cannabis use leading to PLEs). Objectives: To estimate genetic and environmental correlations between cannabis use and PLEs, and to examine PLEs in twin and nontwin sibling pairs discordant for exposure to cannabis use to disentangle predispositional from individual-specific effects. Design, Setting, and Participants: In this cross-sectional analysis, diagnostic interviews and self-reported data were collected from 2 separate population-based samples of twin and nontwin sibling pairs. Data from the Human Connectome Project were collected between August 10, 2012, and September 29, 2015, and data from the Australian Twin Registry Cohort 3 (ATR3) were collected between August 1, 2005, and August 31, 2010. Data were analyzed between August 17, 2017, and July 6, 2018. The study included data from 1188 Human Connectome Project participants and 3486 ATR3 participants, totaling 4674 participants. Main Outcomes and Measures: Three cannabis-involvement variables were examined: frequent use (ie, ≥100 times), a DSM-IV lifetime cannabis use disorder diagnosis, and current cannabis use. Genetic and environmental correlations between cannabis involvement and PLEs were estimated. Generalized linear mixed models examined PLE differences in twin and nontwin sibling pairs discordant for cannabis use. Results: Among the 4674 participants, the mean (SD) age was 30.5 (3.2) years, and 2923 (62.5%) were female. Data on race/ethnicity were not included as a covariate owing to lack of variability within the ATR3 sample; among the 1188 participants in the Human Connectome Project, 875 (73.7%) were white. Psychotic-like experiences were associated with frequent cannabis use (ß = 0.11; 95% CI, 0.08-0.14), cannabis use disorder (ß = 0.13; 95% CI, 0.09-0.16), and current cannabis use (ß = 0.07; 95% CI, 0.04-0.10) even after adjustment for covariates. Correlated genetic factors explained between 69.2% and 84.1% of this observed association. Within discordant pairs of twins/siblings (Npairs, 308-324), Psychotic-like experiences were more common in cannabis-exposed individuals compared with their relative who used cannabis to a lesser degree (ß ≥ .23, P < .05; eg, frequent and infrequent cannabis-using relatives significantly differed, z = -5.41; P < .001). Conclusions and Relevance: Despite the strong contribution of shared genetic factors, frequent and problem cannabis use also appears to be associated with PLEs via person-specific pathways. This study's findings suggest that policy discussions surrounding legalization should consider the influence of escalations in cannabis use on traitlike indices of vulnerability, such as PLEs, which could contribute to pervasive psychological and interpersonal burden.
Asunto(s)
Predisposición Genética a la Enfermedad , Abuso de Marihuana/complicaciones , Psicosis Inducidas por Sustancias/etiología , Adulto , Estudios Transversales , Enfermedades en Gemelos/etiología , Enfermedades en Gemelos/genética , Enfermedades en Gemelos/psicología , Femenino , Humanos , Entrevista Psicológica , Masculino , Abuso de Marihuana/psicología , Psicosis Inducidas por Sustancias/genética , Sistema de Registros , Factores de Riesgo , Hermanos/psicologíaRESUMEN
Genetic and sociodemographic risk factors potentially associated with cannabis use (CU) were investigated in 40 cannabis users and 96 control subjects. DNA methylation analyses were also performed to explore the possibility of epigenetic changes related to CU. We conducted a candidate gene association study that included variants involved in the dopaminergic (ANKK1, NCAM1 genes) and endocannabinoid (CNR1, CNR2 gene) pathways. Sociodemographic data included gender, marital status, level of education, and body mass index. We used MeDIP-qPCR to test whether variations in DNA methylation might be associated with CU. We found a significant association between SNP rs1049353 of CNR1 gene (p = 0.01) and CU. Differences were also observed related to rs2501431 of CNR2 gene (p = 0.058). A higher education level appears to decrease the risk of CU. Interestingly, females were less likely to use cannabis than males. There was a significantly higher level of DNA methylation in cannabis users compared to controls in two of the genes tested: hypermethylation at exon 8 of DRD2 gene (p = 0.034) and at the CpG-rich region in the NCAM1 gene (p = 0.0004). Both genetic variants and educational attainment were also related to CU. The higher rate of DNA methylation, evidenced among cannabis users, may be either a marker of CU or a consequence of long-term exposure to cannabis. The identified genetic variants and the differentially methylated regions may represent biomarkers and/or potential targets for designs of pharmacological therapeutic agents. Our observations also suggest that educational programs may be useful strategies for CU prevention.
Asunto(s)
Metilación de ADN , Escolaridad , Variación Genética , Abuso de Marihuana/genética , Psicosis Inducidas por Sustancias/etiología , Adolescente , Adulto , Estudios de Casos y Controles , Epigénesis Genética , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Psicosis Inducidas por Sustancias/genética , Adulto JovenRESUMEN
Methamphetamine (METH) is an addictive psychostimulant drug commonly leading to schizophrenia-like psychotic symptoms. Disturbances in glutamatergic neurotransmission have been proposed as neurobiological mechanisms and the α-amino-3 hydroxy-5 methyl-4 isoxazole propionic acid (AMPA) glutamate receptor has been implicated in these processes. Moreover, genetic variants in GRIAs, genes encoding AMPA receptor subunits, have been observed in association with both drug dependence and psychosis. We hypothesized that variation of GRIA genes may be associated with METH dependence and METH-induced psychosis. Genotyping of GRIA1 rs1428920, GRIA2 rs3813296, GRIA3 rs3761554, rs502434 and rs989638 was performed in 102 male Thai controls and 100 METH-dependent subjects (53 with METH-dependent psychosis). We observed no evidence of association with METH dependence and METH-dependent psychosis in the GRIA1 and GRIA2 polymorphisms, nor with single polymorphisms rs3761554 and rs989638 in GRIA3. An association of GRIA3 rs502434 was identified with both METH dependence and METH-dependent psychosis, although this did not withstand correction for multiple testing. Combining the analysis of this site with the previously-demonstrated association with BDNF rs6265 resulted in a highly significant effect. These preliminary findings indicate that genetic variability in GRIA3 may interact with a functional BDNF polymorphism to provide a strong risk factor for the development of METH dependence in the Thai population.
Asunto(s)
Trastornos Relacionados con Anfetaminas/genética , Predisposición Genética a la Enfermedad/genética , Metanfetamina/efectos adversos , Polimorfismo de Nucleótido Simple/genética , Psicosis Inducidas por Sustancias/genética , Trastornos Psicóticos/genética , Receptores AMPA/genética , Adulto , Pueblo Asiatico , Factor Neurotrófico Derivado del Encéfalo/genética , Estudios de Casos y Controles , Estimulantes del Sistema Nervioso Central/efectos adversos , Frecuencia de los Genes/genética , Estudios de Asociación Genética , Humanos , Masculino , Persona de Mediana Edad , Esquizofrenia/inducido químicamente , Esquizofrenia/genética , Adulto JovenRESUMEN
Objective: COMT rs4680 (Val158Met) genotype moderates the effect of cannabis on the age of onset of psychosis (AoP). We investigated the association between rs4680 and AoP, after adjusting for relevant covariates, in a Canadian Caucasian sample. Methods: One hundred and sixty-nine subjects with psychosis were recruited. AoP, defined as age of DSM-IV diagnosis was established using the Structured Clinical Interview for DSM-IV. Cannabis use data were collected using a self-report computerized questionnaire. DNA was extracted from saliva and genotyping of the COMT Val158Met polymorphism was done by SNaPshot and TaqMan assays. Kaplan-Meier analysis results are reported. Results: In those who had used cannabis before 20 years of age, rs4680 had a trend level effect on AoP (median AoP: Val/Val < Val/Met < Met/Met 19.37, 20.95, 21.24 years, respectively; log-rank test p = .051). Conclusion: Our data are indicative of the need to further investigate the association between the COMT rs4680 variant and AoP in the context of adolescent cannabis use.
Asunto(s)
Cannabis/efectos adversos , Catecol O-Metiltransferasa/genética , Abuso de Marihuana , Psicosis Inducidas por Sustancias , Adolescente , Adulto , Edad de Inicio , Canadá/epidemiología , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Abuso de Marihuana/epidemiología , Abuso de Marihuana/genética , Polimorfismo de Nucleótido Simple , Psicosis Inducidas por Sustancias/epidemiología , Psicosis Inducidas por Sustancias/genética , Encuestas y CuestionariosRESUMEN
AIM: The parvalbumin (PV)-containing subgroup of GABAergic neurons is particularly affected in schizophrenia and animal models of psychosis, including after methamphetamine (METH) administration. We investigated whether METH dependence and METH-induced psychosis may involve an effect on DNA methylation of the PVALB promoter. MATERIALS & METHODS: The methylation of a PVALB promoter sequence was determined in 100 METH-dependent and 102 control subjects using pyrosequencing. RESULTS: A significant increase in PVALB methylation was observed in METH dependence and METH-induced psychosis. No significant effect on long interspersed nucleotide element-1 methylation, a measure of global DNA methylation, was observed. CONCLUSION: These results demonstrate a specific association between elevated PVALB methylation and METH-induced psychosis. This finding may contribute to the GABAergic deficits associated with METH dependence.
Asunto(s)
Trastornos Relacionados con Anfetaminas/genética , Metilación de ADN , Metanfetamina/toxicidad , Parvalbúminas/genética , Regiones Promotoras Genéticas , Psicosis Inducidas por Sustancias/genética , Adulto , Humanos , MasculinoRESUMEN
GABA system genes have been implicated in neurotrophy and neurogenesis, which play pivotal roles in an individual's variation in vulnerability to amphetamine addiction or amphetamine-induced psychosis (AIP). We hypothesized that common genetic variants in the GABA system genes may be associated with amphetamine-induced psychotic disorder. In our study, thirty-six single nucleotide polymorphisms (SNPs) within the GABA system genes were genotyped in 400 amphetamine-induced psychotic disorder patients and 400 amphetamine use disorders patients (AUP) (not including those categorized as psychosis) in the Han Chinese population. In this study, 51.88% of the Han Chinese amphetamine-type substance use disorder patients met the criteria of amphetamine-induced psychotic disorder, and 79.5% amphetamine-induced psychotic disorder patients had auditory hallucinations, while 46.5% had delusions of reference. The allele frequency of rs1129647 showed nominal association with AIP in the Han Chinese population (P=0.03). Compared with AUP group patients, T allele frequency of AIP group patients was significantly increased. The adjustment for age and gender factors in the AIP and AUP patients was executed using unconditional logistic regression under five inheritance models. The genotype frequency of rs1129647 showed nominal association with AIP in the log-additive model (P=0.04). The genotype frequency of rs2290733 showed nominal association with AIP in the recessive model (P=0.04). Compared with female AIP patients, male patients were more likely to have the CC genotype of rs17545383 (P=0.04). Moreover, we determined that more male patients carried the T allele of rs2290733 in the AIP group (P=0.004). Unfortunately, the significant differences did not survive Benjamini-Hochberg false discovery rate correction (adjusted P>0.05). No association between the SNPs of the GABA system genes and amphetamine-induced psychotic disorder risk was identified. No haplotype of the GABA system genes affected amphetamine-induced psychotic disorder risk. This report describes the first association study between the GABA system genes and amphetamine-induced psychotic disorder in the Han Chinese population. Our data may provide a reference for future research.
Asunto(s)
Anfetamina/efectos adversos , Psicosis Inducidas por Sustancias/genética , Ácido gamma-Aminobutírico/genética , Adulto , Pueblo Asiatico , Estudios de Casos y Controles , Femenino , Frecuencia de los Genes , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Humanos , Masculino , Polimorfismo de Nucleótido Simple , Psicosis Inducidas por Sustancias/etnología , Receptores de GABA-A/genética , RiesgoRESUMEN
Some of the most compelling evidence supporting an association between cannabinoid agonists and psychosis comes from controlled laboratory studies in humans. Randomized, double-blind, placebo-controlled, crossover laboratory studies demonstrate that cannabinoid agonists, including phytocannabinoids and synthetic cannabinoids, produce a wide range of positive, negative, and cognitive symptoms and psychophysiologic deficits in healthy human subjects that resemble the phenomenology of schizophrenia. These effects are time locked to drug administration, are dose related, and are transient and rarely necessitate intervention. The magnitude of effects is similar to the effects of ketamine but qualitatively distinct from other psychotomimetic drugs, including ketamine, amphetamine, and salvinorin A. Cannabinoid agonists have also been shown to transiently exacerbate symptoms in individuals with schizophrenia in laboratory studies. Patients with schizophrenia are more vulnerable than healthy control subjects to the acute behavioral and cognitive effects of cannabinoid agonists and experience transient exacerbation of symptoms despite treatment with antipsychotic medications. Furthermore, laboratory studies have failed to demonstrate any "beneficial" effects of cannabinoid agonists in individuals with schizophrenia-challenging the cannabis self-medication hypothesis. Emerging evidence suggests that polymorphisms of several genes related to dopamine metabolism (e.g., COMT, DAT1, and AKT1) may moderate the effects of cannabinoid agonists in laboratory studies. Cannabinoid agonists induce dopamine release, although the magnitude of release does not appear to be commensurate to the magnitude and spectrum of their acute psychotomimetic effects. Interactions between the endocannabinoid, gamma-aminobutyric acid, and glutamate systems and their individual and interactive effects on neural oscillations provide a plausible mechanism underlying the psychotomimetic effects of cannabinoids.
Asunto(s)
Agonistas de Receptores de Cannabinoides/efectos adversos , Cannabinoides/efectos adversos , Dopamina/metabolismo , Psicosis Inducidas por Sustancias/fisiopatología , Esquizofrenia/fisiopatología , Agonistas de Receptores de Cannabinoides/farmacología , Cannabinoides/farmacología , Catecol O-Metiltransferasa/genética , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/genética , Endocannabinoides/metabolismo , Humanos , Proteínas Proto-Oncogénicas c-akt/genética , Psicosis Inducidas por Sustancias/genética , Ensayos Clínicos Controlados Aleatorios como Asunto , Esquizofrenia/genéticaRESUMEN
Cannabis use can induce cognitive impairments and psychotic experiences. A functional polymorphism in the catechol-O-methyltransferase (COMT) gene (Val(158)Met) appears to influence the immediate cognitive and psychotic effects of cannabis, or ∆(9)-tetrahydrocannabinol (THC), its primary psychoactive ingredient. This study investigated the moderation of the impact of experimentally administered THC by COMT. Cognitive performance and psychotic experiences were studied in participants without a psychiatric diagnosis, using a between-subjects design (THC vs. placebo). The effect of COMT Val(158)Met genotype on the cognitive and psychotic effects of THC, administered intravenously in a double-blind, placebo-controlled manner to 78 participants who were vulnerable to paranoia, was examined. The results showed interactive effects of genotype and drug group (THC or placebo) on working memory, assayed using the Digit Span Backwards task. Specifically, THC impaired performance in COMT Val/Val, but not Met, carriers. In contrast, the effect of THC on psychotic experiences, measured using the Community Assessment of Psychic Experiences (CAPE) positive dimension, was unaffected by COMT genotype. This study is the largest to date examining the impact of COMT genotype on response to experimentally administered THC, and the first using a purely non-clinical cohort. The data suggest that COMT genotype moderates the cognitive, but not the psychotic, effects of acutely administered THC.
Asunto(s)
Catecol O-Metiltransferasa/genética , Cognición/efectos de los fármacos , Dronabinol/farmacología , Memoria a Corto Plazo/efectos de los fármacos , Psicosis Inducidas por Sustancias/genética , Psicosis Inducidas por Sustancias/psicología , Adulto , Método Doble Ciego , Femenino , Genotipo , Humanos , Masculino , Polimorfismo Genético/genéticaRESUMEN
AIM: Association of the brain-derived neurotrophic factor (BDNF) genetic polymorphism rs6265 (Val66Met) with methamphetamine (METH) dependence and METH-induced psychosis was investigated in the Thai population. MATERIALS & METHODS: The rs6265 genotype was determined in 100 male METH-dependent subjects and 102 controls using a real-time PCR high-resolution melt (RT-PCR-HRM) assay. RESULTS: The rs6265 genotype demonstrated significant differences in distribution between METH-dependent subjects and controls in which the frequency of GG genotype versus A-allele carriers was associated with METH dependence. Moreover, a significant effect of genotype on the occurrence of psychosis was found, with a lower frequency of GG genotype associated with METH-induced psychosis. CONCLUSION: The present findings indicate that rs6265 is associated with METH dependence in the Thai population, with the GG genotype greater in METH-dependent subjects but reducing the emergence of METH-dependent psychosis.
Asunto(s)
Trastornos Relacionados con Anfetaminas/genética , Factor Neurotrófico Derivado del Encéfalo/genética , Estimulantes del Sistema Nervioso Central , Metanfetamina , Polimorfismo Genético/genética , Trastornos Relacionados con Anfetaminas/epidemiología , Pueblo Asiatico/genética , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Frecuencia de los Genes , Genotipo , Humanos , Psicosis Inducidas por Sustancias/epidemiología , Psicosis Inducidas por Sustancias/genética , Tailandia/epidemiologíaRESUMEN
OBJECTIVE: Beta-blockers are commonly used in the treatment of hypertension and cardiac arrhythmias. The incidence of neuropsychiatric side effects is generally low. This case report shows the potential familial liability of a metoprolol-induced psychosis. METHOD: We report a case of metoprolol-induced psychosis. Potential pharmocogenetic factors mediating this familial metoprolol-induced psychosis are discussed. RESULTS: A middle-aged man developed psychosis after starting metoprolol, which diminished after ceasing the medication. Two of his family members experienced similar symptoms after using metoprolol. All family members were genotyped as CYP2D6*4 allele carriers indicating reduced CYP2D6 enzyme activity. CONCLUSION: The case presented here suggests a potential familial liability for metoprolol- induced psychosis. Pharmacokinetic mechanisms are hypothesized to mediate this familial liability through genetic variation in the CYP2D6 genotype. A family history of psychotic symptoms after treatment with beta-blockers should be taken into account, when prescribing this beta-blocker.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 1/efectos adversos , Predisposición Genética a la Enfermedad , Metoprolol/efectos adversos , Psicosis Inducidas por Sustancias/genética , Adulto , Citocromo P-450 CYP2D6/genética , Humanos , MasculinoRESUMEN
Both cannabis use and the dopamine receptor (DRD2) gene have been associated with schizophrenia, psychosis-like experiences, and cognition. However, there are no published data investigating whether genetically determined variation in DRD2 dopaminergic signaling might play a role in individual susceptibility to cannabis-associated psychosis. We genotyped (1) a case-control study of 272 patients with their first episode of psychosis and 234 controls, and also from (2) a sample of 252 healthy subjects, for functional variation in DRD2, rs1076560. Data on history of cannabis use were collected on all the studied subjects by administering the Cannabis Experience Questionnaire. In the healthy subjects' sample, we also collected data on schizotypy and cognitive performance using the Schizotypal Personality Questionnaire and the N-back working memory task. In the case-control study, we found a significant interaction between the rs1076560 DRD2 genotype and cannabis use in influencing the likelihood of a psychotic disorder. Among cannabis users, carriers of the DRD2, rs1076560, T allele showed a 3-fold increased probability to suffer a psychotic disorder compared with GG carriers (OR = 3.07; 95% confidence interval [CI]: 1.22-7.63). Among daily users, T carrying subjects showed a 5-fold increase in the odds of psychosis compared to GG carriers (OR = 4.82; 95% CI: 1.39-16.71). Among the healthy subjects, T carrying cannabis users had increased schizotypy compared with T carrying cannabis-naïve subjects, GG cannabis users, and GG cannabis-naïve subjects (all P ≤ .025). T carrying cannabis users had reduced working memory accuracy compared with the other groups (all P ≤ .008). Thus, variation of the DRD2, rs1076560, genotype may modulate the psychosis-inducing effect of cannabis use.
Asunto(s)
Cannabis/efectos adversos , Memoria a Corto Plazo/fisiología , Psicosis Inducidas por Sustancias/genética , Receptores de Dopamina D2/genética , Esquizofrenia/genética , Trastorno de la Personalidad Esquizotípica/genética , Adolescente , Adulto , Estudios de Casos y Controles , Susceptibilidad a Enfermedades , Femenino , Interacción Gen-Ambiente , Humanos , Masculino , Persona de Mediana Edad , Riesgo , Adulto JovenRESUMEN
For more than 40 years following its approval by the Food and Drug Administration (FDA) as an anesthetic, ketamine, a non-competitive N-methyl-D-aspartic acid (NMDA) receptor antagonist, has been used as a tool of psychiatric research. As a psychedelic drug, ketamine induces psychotic symptoms, cognitive impairment, and mood elevation, which resemble some symptoms of schizophrenia. Recreational use of ketamine has been increasing in recent years. However, little is known of the underlying molecular mechanisms responsible for ketamine-associated psychosis. Recent animal studies have shown that repeated ketamine administration significantly increases NMDA receptor subunit gene expression, in particular subunit 1 (NR1 or GluN1) levels. This results in neurodegeneration, supporting a potential mechanism where up-regulation of NMDA receptors could produce cognitive deficits in chronic ketamine abuse patients. In other studies, NMDA receptor gene variants are associated with addictive behavior. Here, we focus on the roles of NMDA receptor gene subunits in ketamine abuse and ketamine psychosis and propose that full sequencing of NMDA receptor genes may help explain individual vulnerability to ketamine abuse and ketamine-associated psychosis.
Asunto(s)
Antagonistas de Aminoácidos Excitadores/efectos adversos , Regulación de la Expresión Génica/efectos de los fármacos , Predisposición Genética a la Enfermedad , Drogas Ilícitas/efectos adversos , Ketamina/efectos adversos , Psicosis Inducidas por Sustancias , Receptores de N-Metil-D-Aspartato , Trastornos Relacionados con Sustancias , Humanos , Enfermedades Neurodegenerativas/inducido químicamente , Enfermedades Neurodegenerativas/metabolismo , Psicosis Inducidas por Sustancias/genética , Psicosis Inducidas por Sustancias/metabolismo , Psicosis Inducidas por Sustancias/patología , Receptores de N-Metil-D-Aspartato/biosíntesis , Receptores de N-Metil-D-Aspartato/genética , Trastornos Relacionados con Sustancias/genética , Trastornos Relacionados con Sustancias/metabolismo , Trastornos Relacionados con Sustancias/patologíaRESUMEN
OBJECTIVE: The contribution contains a comparison of the history data of adolescent patients hospitalized at the Department of Child Psychiatry, Children´s Faculty Hospital in Bratislava with the diagnoses of Substance-Induced Psychosis (SIP), Early Onset Schizophrenia (EOS) and with Substance Use Disorders (SUD). BACKGROUND: SIP is rarely recorded and little documented by the age of 18. The etiology of this disorder is still relatively unclear. METHODS: The data collection was carried out from patients hospitalized between January 1, 2001 and December 31, 2012. We recorded data from 20 patients hospitalized with SIP, 50 patients hospitalized with EOS, and 50 patients hospitalized with SUD. We collected and compared the data on family history, perinatal complications, early psychomotor development, data on psychical problems before their hospitalization, and presence of unfavorable life situations in their childhood. CONCLUSION: The data of adolescents with SIP are more similar to the data of patients with EOS than patients with SUD in terms of the burden of family history, the frequency of complications during pregnancy and delivery, and the frequency of the subsequent early psychomotor impairment. In terms of unfavorable life situations and psychological problems for which they were monitored in a psychiatric ward before their hospitalization with SIP, their data are more similar to those of patients with SUD than with EOS (Tab. 3, Fig. 1, Ref. 21).
Asunto(s)
Psicosis Inducidas por Sustancias/diagnóstico , Esquizofrenia/diagnóstico , Trastornos Relacionados con Sustancias/diagnóstico , Adolescente , Femenino , Predisposición Genética a la Enfermedad , Humanos , Masculino , Embarazo , Complicaciones del Embarazo/psicología , Servicio de Psiquiatría en Hospital , Psicosis Inducidas por Sustancias/genética , Psicosis Inducidas por Sustancias/psicología , Esquizofrenia/genética , Psicología del Esquizofrénico , Eslovaquia , Trastornos Relacionados con Sustancias/genética , Trastornos Relacionados con Sustancias/psicologíaRESUMEN
This article presents two cases of adolescent males who were admitted to our inpatient psychiatric unit with a psychotic, disorganized presentation. Both males had a genetic vulnerability to mental illness and reported significant substance use. Their symptoms were refractory to treatment and required the use of clozapine. Both patients experienced significant side effects, which limited the maximum daily dose of clozapine. However, they responded to a dose that was much lower than that typically used in adults. There is significant evidence in the literature about cannabis use triggering psychotic breaks in vulnerable individuals. We speculate that substance use (including synthetic cannabinoids) triggers treatment-resistant psychosis that requires the use of clozapine. Further, lower doses of clozapine may be sufficient to treat the substance-induced psychotic symptoms than those typically used in adult schizophrenia.
Asunto(s)
Antipsicóticos/uso terapéutico , Clozapina/uso terapéutico , Predisposición Genética a la Enfermedad , Fumar Marihuana/efectos adversos , Psicosis Inducidas por Sustancias/tratamiento farmacológico , Psicosis Inducidas por Sustancias/genética , Adolescente , Humanos , MasculinoRESUMEN
To investigate the involvement of COMT Val158Met and DAT1 3'-UTR VNTR genotypes in the pathogenesis of illicit drug use and drug-induced psychotic disorders (DIP), 187 substance users and 386 normal controls were recruited from Northern Taiwan. Substance users and normal controls significantly differed in allele frequencies of COMT Val158Met (p = 0.039) but not in allele frequencies of DAT1 3'-UTR VNTR (p = 0.879). However, neither allele frequencies of COMT Val158Met nor allele frequencies of DAT1 3'-UTR VNTR were associated with DIP. The findings should be confirmed in further studies of a larger sample size and a more homogenous patient group.
Asunto(s)
Catecol O-Metiltransferasa/genética , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/genética , Psicosis Inducidas por Sustancias/genética , Trastornos Relacionados con Sustancias/genética , Adulto , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Drogas Ilícitas , Masculino , Polimorfismo de Nucleótido Simple , Taiwán , Adulto JovenRESUMEN
AIMS: To explore the clinical features of methamphetamine-induced paranoia (MIP) and associations between MIP and a genetic polymorphism in dopamine ß-hydroxylase (DBH-1021CâT). DESIGN: Retrospective analysis of clinical presentation and genetic association by χ(2) test and logistic regression analysis. SETTING: A Thai substance abuse treatment center. PARTICIPANTS: A total of 727 methamphetamine-dependent (MD) individuals. MEASUREMENTS: Clinical: Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA) and the Methamphetamine Experience Questionnaire (MEQ). Genetic: DBH-1021CâT. FINDINGS: Forty per cent of individuals (289 of 727; 39.8%) with MD had MIP. Within-binge latency to MIP onset occurred more rapidly in the most recent compared with initial MIP episode (P = 0.02), despite unchanging intake (P = 0.89). Individuals with MIP were significantly less likely to carry lower (TT/CT) compared with higher (CC) activity genotypes (34.3 versus 43.3%; χ(2) 1 = 5, P = 0.03). DBH effects were confirmed [odds ratio (OR) = 0.7, P = 0.04] after controlling for associated clinical variables (MD severity, OR = 3.4, P < 0.001; antisocial personality disorder, OR = 2.2, P < 0.001; alcohol dependence, OR = 1.4, P = 0.05; and nicotine dependence, OR = 1.4, P = 0.06). TT/CT carriers were more likely to initiate cigarette smoking (OR = 3.9, P = 0.003) and probably less likely to be dependent on alcohol (OR = 0.6, P = 0.05). CONCLUSIONS: Among methamphetamine-dependent individuals, paranoia appears to occur increasingly rapidly in the course of a session of methamphetamine use. Severity of methamphetamine dependence and antisocial personality disorder predicts methamphetamine-induced paranoia. The genetic polymorphism in dopamine ß-hydroxylase is associated with methamphetamine-induced paranoia and influences smoking initiation.